A normal view of the Facilities for Illness Management and Prevention (CDC) headquarters in Atlanta, Georgia September 30, 2014. REUTERS/Tami Chappell
Oct 27 (Reuters) – An advisory panel of the U.S. Facilities for Illness Management and Prevention will meet on Nov. 2 to debate using COVID-19 vaccines in kids aged between 5 and 11 years.
Advisors to the U.S. Meals and Drug Administration had on Tuesday voted overwhelmingly to suggest that the regulator authorize Pfizer (PFE.N) and BioNTech’s vaccine for youthful kids. read more
The shot has been licensed for ages 12-15 since Might and it was cleared for these aged 16 and above in December final yr.
Reporting by Amruta Khandekar; Modifying by Arun Koyyur
Our Requirements: The Thomson Reuters Trust Principles.
0 Comments